Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Systemic Lupus Erythematosus | Phase 1 | CN | 20 Jul 2024 | |
Leukemia | Phase 1 | CN | 22 Aug 2022 | |
Lymphoma | Phase 1 | CN | 22 Aug 2022 | |
Pre B-cell acute lymphoblastic leukemia | Phase 1 | CN | 07 Jun 2021 | |
B-Cell Lymphoma | Phase 1 | CN | 10 Sep 2019 | |
B-cell lymphoma recurrent | Preclinical | - | 15 Sep 2019 | |
B-cell lymphoma refractory | Preclinical | - | 15 Sep 2019 | |
B-Cell Leukemia | Preclinical | CN | 08 Sep 2017 |